The global stock market has taken a big hit recently due to the ongoing coronavirus pandemic. While the GSK share price has also dropped, investors may see it GlaxoSmithKline shares as a safer long-term bet, especially given its history with developing vaccines. GlaxoSmithKline plc (LON:GSK) is a British pharmaceutical company based in Brentford. It is part of the FTSE 100 and helped developed the world’s first malaria vaccine in 2014.
GSK plc (GSK) is a publicly traded drug manufacturers-general business based in the UK. It opened the day at 1322.2p after a previous close of 1319.6p. During the day the price has varied from a low of 1311.2p to a high of 1341.4p. The latest price was 1330.6p (25 minute delay). GSK is listed on the London Stock Exchange (LSE) and employs 90,096 staff. All prices are listed in pence sterling.
Best for
0% commission
Best for
Beginner investments
Best for
Mobile app
Best for
Index funds
Share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | $10 | £0.00 £665.30 total |
Capital at risk |
|
£0 | £250 | £8.00 £673.30 total |
Capital at risk |
|
£0 | No minimum | £0.00 £665.30 total |
Capital at risk |
 |
£0 | £1 | £11.95 £677.25 total |
Capital at risk |
 |
£0 | £0.01 | £1.84 £667.14 total |
Capital at risk |
 |
£9.99 per month | No minimum | £7.99 £673.29 total |
Capital at risk |
 |
£36 per year | £20 | £9.50 £674.80 total |
Capital at risk |
Full comparison of share dealing platforms
Historical closes compared with the last close of 1330.6p
| 1 week (2022-09-27) | 0.70% |
|---|---|
| 1 month (2022-09-02) | -1.58% |
| 3 months (2022-07-04) | -40.95% |
| 6 months (2022-04-04) | -35.60% |
| 1 year (2021-10-04) | -23.13% |
|---|---|
| 2 years (2020-10-02) | -26.31% |
| 3 years (2019-10-04) | -37.35% |
| 5 years (2017-10-04) | -12.82% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
GSK's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 11x. In other words, GSK shares trade at around 11x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
However, GSK's P/E ratio is best considered in relation to those of others within the drug manufacturers-general industry or those of similar companies.
GSK's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3448. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GSK's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider GSK's PEG ratio in relation to those of similar companies.
GSK's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping £11.1 billion.
The EBITDA is a measure of a GSK's overall financial performance and is widely used to measure a its profitability.
To put that into context you can compare it against similar companies.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like GSK.
GSK's total ESG risk: 28.51
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and GSK's overall score of 28.51 (as at 01/01/2019) is pretty good – landing it in it in the 35th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like GSK is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
To gain some more context, you can compare GSK's total ESG risk score against those of similar companies.
GSK's environmental score: 3.88/100
GSK's environmental score of 3.88 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that GSK is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
GSK's social score: 16.94/100
GSK's social score of 16.94 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that GSK is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
GSK's governance score: 9.69/100
GSK's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that GSK is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
GSK's controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, GSK scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that GSK hasn't always managed to keep its nose clean.
Wondering how that compares? Below are the controversy scores of similar companies.
GSK plc was last rated for ESG on: 2019-01-01.
| Total ESG score | 28.51 |
|---|---|
| Total ESG percentile | 34.54 |
| Environmental score | 3.88 |
| Environmental score percentile | 6 |
| Social score | 16.94 |
| Social score percentile | 6 |
| Governance score | 9.69 |
| Governance score percentile | 6 |
| Level of controversy | 3 |
| Open | 1322.2p |
|---|---|
| High | 1341.4p |
| Low | 1311.2p |
| Close | 1330.6p |
| Previous close | 1319.6p |
| Change | 11p |
| Change % | 0.8336% |
| Volume | 7,077,633 |
| 52-week range | 1280.92p - 1821.6021p |
|---|---|
| 50-day moving average | 1448.512p |
| 200-day moving average | 1632.4528p |
| Wall St. target price | 2128.25p |
| PE ratio | 11.4544 |
| Dividend yield | 86.3p (6.61%) |
| Earnings per share (TTM) | 1.14p |
Dividend yield: 6.61% of stock value
Forward annual dividend yield: 6.61% of stock value
Dividend payout ratio: 55.71% of net profits
GSK has recently paid out dividends equivalent to 6.61% of its share value annually.
GSK has paid out, on average, around 55.71% of recent net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 6.61% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), shareholders could enjoy a 6.61% return on their shares, in the form of dividend payments. In GSK's case, that would currently equate to about 86.3p per share.
GSK's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 18 August 2022 (the "ex-dividend date").
GSK's dividend yield is perhaps best considered in relation to those of similar companies.
Over the last 12 months, GSK's shares have ranged in value from as little as 1280.92p up to 1821.6021p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while GSK's is 0.2588. This would suggest that GSK's shares are less volatile than average (for this exchange).
To put GSK's beta into context you can compare it against those of similar companies.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Ever wondered how to buy shares in Veru? We explain how and compare a range of providers that can give you access to many brands, including Veru.
Ever wondered how to buy shares in C4 Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including C4 Therapeutics.
Ever wondered how to buy shares in Clever Leaves? We explain how and compare a range of providers that can give you access to many brands, including Clever Leaves.
Mental health stocks can be rewarding, but there are risks involved that could impact your profits. Find out how to invest in companies in the mental health industry.
Pharma stocks can be rewarding, but there are risks involved that could impact your profits. Find out the best way to invest in pharma stock.
Ever wondered how to buy shares in Bone Biologics? We explain how and compare a range of providers that can give you access to many brands, including Bone Biologics.
Ever wondered how to buy shares in Adagio Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Adagio.
Ever wondered how to buy shares in Bolt Biotherapeutics? We explain how and compare a range of providers that can give you access to many brands, including Bolt Biotherapeutics.
Ever wondered how to buy shares in Vallon Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Vallon Pharmaceuticals.
Ever wondered how to buy shares in Qualigen Therapeutics? We explain how and compare a range of providers that can give you access to many brands, including Qualigen.
